Gallbladder Carcinoma Clinical Trial
Official title:
A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients
This research will be the first study for exosome purified from blood in gallbladder carcinoma patients. Proteomics studies will be done in both tumor tissue and the circulating exosome from blood specimens. Then, the potential prognostic and predictive biomarkers will be searched by bioinformatics to find the correlations between exosome biomarkers and gallbladder carcinoma.
Background:
Exosomes are formed by inward budding of late endosomes, producing multivesicular bodies
(MVBs), and are released into the environment by fusion of the MVBs with the plasma membrane.
It has been demonstrated that the content and function of exosomes depends on the originating
cell and the conditions under which they are produced. Tumor exosome production, transfer and
education of bone marrow cells supports tumor growth and metastasis.
Aims of the study:
Proteomics studies will be done in both tumor tissue and the circulating exosome from the
gallbladder carcinoma patients. Then, the potential prognostic and predictive biomarkers will
be searched by bioinformatics to find the correlations between exosome biomarkers and
gallbladder carcinoma.
Materials and Methods:
The investigators will conduct a case-control study in 11 hospitals from China. Cases will be
the patients with newly-diagnosed gallbladder carcinoma. The controls will be matched （1：1）by
sex，race and age which will be selected from the patients receiving cholecystectomy due to
gallstones from the same hospital with the cases. A total of 50 patients with gallbladder
carcinoma will be recruited. The investigators will obtain the blood and tumor tissue samples
for further analysis of proteomics studies. Exosome from blood specimens will be isolated and
purified by sucrose gradient ultracentrifugation. The potential prognostic and predictive
biomarkers will be searched by bioinformatics to find the correlations between exosome
biomarkers and gallbladder carcinoma. Data will be collected from January 2018 to December
2018.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05285358 -
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
|
Phase 1 | |
| Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04853017 -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05222854 -
Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"
|
||
| Not yet recruiting |
NCT05681949 -
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
|
N/A | |
| Active, not recruiting |
NCT02151084 -
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
|
Phase 2 | |
| Terminated |
NCT01855724 -
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
|
Phase 2 | |
| Withdrawn |
NCT02105350 -
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
|
Phase 1 | |
| Recruiting |
NCT04183712 -
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
|
Phase 2 | |
| Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
| Completed |
NCT02649712 -
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
|
N/A | |
| Recruiting |
NCT05194072 -
A Study of SGN-B7H4V in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT03201458 -
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
|
Phase 2 | |
| Completed |
NCT04740164 -
A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP
|
N/A | |
| Completed |
NCT02333188 -
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
|
Phase 1 | |
| Recruiting |
NCT05712356 -
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A | |
| Recruiting |
NCT03702491 -
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04068194 -
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
|
Phase 1/Phase 2 |